

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date: February 8, 2005	Attorney Docket No.	Client Ref.
	056291-5199	10/523836
	Applicant: Stephen Robert WEDGE	
	Appln. No.: To Be Assigned	
	Filing Date: Concurrently	
Examiner: Unassigned		Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Abstract		Readily Available	
						Enclosed	No	Enclosed	No
	GR								
	HR								
	IR								
	JR								
	KR								
	LR								
	MR								
	NR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

OR	Magné et al., British Journal of Cancer, vol. 86, No. 5, 4 March 2002, pp. 819-827				
PR	Ciardello et al., Clinical Cancer Research, The American Association for Cancer Research, vol. 6, no. 5, May 2000, pp. 2053-2063				
QR	Holden et al., European Journal of Cancer, vol. 37, no. Supplement 6, October 2001, p. S73				
RR	Hennequin et al., Journal of Medicinal Chemistry, vol. 45, no. 6, 14 March 2002, pp. 1300-1312				
SR	"Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR 'KDRI-TKI), in a model of ZD1839 ('Iressa') resistance", European Journal of Cancer, vol. 38, November 2002, pp. S60-S61				
TR	Manley et al., Expert Opinion on Investigational Drugs, vol. 11, no. 2, Dec. 2002, pp. 1715-1736				
UR					
VR					

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	